Innovation
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.

Insitro’s Daphne Koller On The Marriage Of Biology And Machine Learning At The Company’s Heart
Industry veteran and serial entrepreneur Daphne Koller tells In Vivo about how her company, Insitro, is unleashing the potential of computational biology and machine learning to discover new drug compounds.

AI Medical Imaging And Radiotherapy First For UK’s NICE
Inaugural artificial intelligence recommendations from NICE on radiotherapy contouring should allow clinicians to spend more time with patients and on complex cases where AI is not an option. But large language models are not appropriate in all cases, cautions Adrian Sutherland, principal healthcare architect at Endava consultancy.

The Power Of AI To Map The Patient Journey
Mapping the patient journey uncovers a wealth of insights into care, diagnosis and intervention. The onset of advanced analytics tools and sensors now augment the pharma industry’s understanding of the challenges of traversing health care systems. Layering AI into the mapping process not only has the power to provide insights into the current clinical pathway, it can be used to predict and intervene in clinical care.

AI In Cough Diagnosis: Making A Vicious Cycle Virtuous
Hyfe is extending AI to acoustics and championing technology it claims can transform the approach to cough management, leading to improved diagnoses, better treatment and superior health outcomes. CMO Peter Small explained the rationale and how AI has inspired a significant leap forward.

Fourth Time Lucky: How Mithra’s Novel Estrogen E4 Is Disrupting The Women’s Health Market
Podcast: Mithra is shaking up the stagnant women’s health market with a brand new estrogenic compound. E4, or estetrol, is a natural estrogen produced by the human fetus during pregnancy, and could represent a major breakthrough in contraceptive and menopause care.

A Passion For Patient Care And De-Risking Disruptive Technologies
Biomedical engineering graduate Cécile Dupont has for the past 12 years helped healthcare technology businesses develop disruptive solutions that positively impact patients’ lives. The current chapter of her career opened in 2017 when she joined Sofinnova MD Start, the early-stage medtech incubator of VC investor Sofinnova Partners, where she is a partner.

Rethinking Commercialization Models In The Age Of Pricing And Access Complexity
In an environment replete with pricing and patient access pressures, top biopharma companies are building commercialization models that emphasize inclusive and diverse decision-making and that integrate digital tools with a human salesforce.

BioBytes: Machine Learning Could Improve Clinical Trial Diversity
With a growing focus on clinical trial diversity, companies are looking for ways to recruit from historically marginalized communities. Machine learning may help meet these diversity goals.

Explaining The Unexplainable: How To Win US FDA’s Trust In Artificially Intelligent Drug Manufacturing
One issue that has surfaced as the pharmaceutical industry responds to the US FDA’s recent discussion paper on manufacturing with AI machine learning models is the question of how to explain what the models are doing.

‘More Than AI’ – AliveCor Tailors ECG Technology To Modern Care Demands
Many use cases potentially suit AliveCor’s smartphone-based ECG device, which delivers medical-grade cardiac data to consumers, patients and doctors on demand. Artificial intelligence is just one element of the technology offering, says the company’s VP, EMEA Stefan Holzer.

Overcoming Roadblocks: Innovations And Collaborations In Cell And Gene Therapy
Bad actors, lack of funding and skilled workforce shortages threaten to hinder the growth of cell and gene therapies. To unleash the transformative power of cell and gene therapies requires the concerted effort of the entire CGT community.

Healthcare In Crisis: A Vision Of More Human And Flexible Healthcare Experiences
Staff burnout, workforce attrition and patient backlogs are testing the resiliency of health systems. Crisis is not too big a word. Against this backdrop, GE HealthCare commissioned a major report, Reimagining Better Health 2023, which suggested ways of increasing trust and confidence in healthcare provider systems as they evolve.

Making Asset Acquisition Frictionless Via Digital Marketplace and AI
Israeli start-up 9xchange is removing some of the friction from the asset sale and acquisition process through its digital marketplace. A partnership with BenevolentAI is also helping users identify repurposing or indication expansion opportunities. In Vivo spoke with 9xchange CEO Anat Naschitz and Benevolent AI's Matthew Fujisawa.

BioBytes: Four Big Pharma Companies Cultivating AI-Based Start-ups
Through an Israeli innovation lab, four big pharma companies are fostering AI-driven start-ups to help solve industry problems.

Pioneering Partnerships And Novel Trial Design Are Reshaping Repurposing In The CNS Space
Repurposing licensed drugs can be an affordable and effective way to bring new treatments to market, but initial efforts tend to lack funding from big pharma. In Vivo takes a closer look at repurposing projects across the central nervous system space, what it is that drives the work forward and how innovative trial design is changing the game.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Article
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.